FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2552649200> ?p ?o ?g. }

• W2552649200 abstract "Abstract Abstract 323 Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T cells (Treg) after Allogeneic Hematopoietic Cell Transplantation (HCT), and is More Effective than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft vs. Host Disease (GVHD) and Moderate to Severe Chronic GVHD Background: Clinical translation of the Treg suppressive potential will require definition of a pharmacologic immune suppressive platform conducive to preferential Treg reconstitution post-HCT. Sirolimus has differential impact on Treg and conventional T cells. Patients and Methods: We performed a prospective, randomized phase II trial of sirolimus (SIR) and tacrolimus (TAC) vs. methotrexate (MTX) and TAC. From 9/2008 to 5/2011, a total of 74 patients were randomized 1:1 to SIR/TAC vs. MTX/TAC, stratified by age (> or ≤ 50) and donor relation (related vs. unrelated). SIR was administered as a 9 mg oral loading dose on day -1, followed by maintenance with 4 mg daily adjusted to target 8–12 ng/ml; SIR was continued for at least 1 year. MTX was 15 mg/m2 on day +1, then 10 mg/m2on days +3, 6, and 11. TAC was administered at 0.02 mg/kg/day IV or equivalent oral dosing starting on day -3. Target TAC levels were 3–7 ng/ml for the SIR arm versus 10–15 ng/ml for the MTX arm and were maintained through day 60. TAC was tapered thereafter in the absence of acute GVHD. Patient age for the whole study was 23 to 69 (median 49) years, and disease diagnoses included AML (23), ALL (15), MDS (9), MM (8), NHL (8), CLL (7), CML (2), and MPD (2). Patients received peripheral blood mobilized stem cells from HLA-A, B, C, and DRB1 matched sibling (n=35) or unrelated donors (n=39). Age, diagnosis, disease risk and donor relation were balanced across the two study arms. Serial peripheral blood samples were obtained at baseline pre-HCT, day 0, and days 30, 90, 180, and 360 post-HCT. Treg were defined by the surface CD4+CD25brightCD127negative phenotype. The reciprocal relationship between negative surface CD127 and high intracellular FoxP3 expression was confirmed in a subset (n=15) of day 30 patient samples (r=0.94). Results: Median percent Tregs among blood CD4 T cells at day 30 was 16.3 (range 12.5–17.9) for SIR versus 9.9 (8.6–13.5) for MTX, p < 0.0001, and 14.6 (10.8–18.1) for SIR and 9.7 (7.5–11.6) for MTX at day 90 post-HCT, p = 0.0009. SIR-treated patients had increased absolute numbers of Treg, and decreased absolute numbers of non-Treg CD4+ cells on days 30 and 90. The 100-day cumulative incidence of grade 2–4 acute GVHD for SIR was 43% (95% CI 30–63%), and 89% (95% CI 80–100%) for MTX, p<0.0001. Grade 3–4 acute GVHD for SIR was 16% (95% CI 7–36%) and 13% (95% CI 5–33%) for MTX, p=0.16. The incidence of any grade chronic GVHD for SIR was 51% (95% CI 34–78%) and 67% (95% CI 52–85%) for MTX, p=0.56. The cumulative incidence of NIH consensus-defined moderate to severe chronic GVHD was 20% (95% CI 9–43%) following SIR, and 63% (95% CI 47–83%) for MTX, p=0.013. Median time to neutrophil engraftment was comparable (SIR 16, range 11–22 days; MTX 16, range 12–28, p=0.57), and platelet engraftment was improved with SIR (SIR 12, range 6–20; MTX 16, range 10–33, p=0.012). No significant differences in peak mucositis, hepatic veno-occlusive disease (VOD), or thrombotic microangiopathy were observed between SIR and MTX. Overall survival did not significantly differ, log-rank p=0.55. Causes of death in SIR included relapse (n=2), and non-relapse death (septicemia 2, acute GVHD 1, chronic GVHD 1, influenza pneumonia 1, RSV pneumonia 1, VOD 1, multi-organ failure 1). Causes of death in the MTX arm were relapse (n=7), and non-relapse death (diffuse alveolar hemorrhage 1, GVHD 1). We performed serial assessment of patient-reported quality of life (QOL) with the FACT-BMT. While those patients in the MTX group had significantly better mean FWB and FACT-G scores at baseline pre-HCT, we did not detect significant differences in any FACT-BMT domain or summary score at day 30 or 90 post-HCT. Further follow up is needed to study longer term recovery of QOL in SIR and MTX treated patients. Conclusions: These results of a randomized, controlled study provide evidence that the combination of SIR/TAC favors Treg recovery and more effectively prevents acute GVHD and moderate to severe chronic GVHD after allogeneic HCT. Disclosures: Alsina: Millennium: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Allergan: Research Funding." @default.
• W2552649200 created "2016-11-30" @default.
• W2552649200 creator A5004386819 @default.
• W2552649200 creator A5009314752 @default.
• W2552649200 creator A5010176911 @default.
• W2552649200 creator A5012866839 @default.
• W2552649200 creator A5017690247 @default.
• W2552649200 creator A5018552863 @default.
• W2552649200 creator A5021394406 @default.
• W2552649200 creator A5035905546 @default.
• W2552649200 creator A5037882458 @default.
• W2552649200 creator A5045667573 @default.
• W2552649200 creator A5051154663 @default.
• W2552649200 creator A5060783496 @default.
• W2552649200 creator A5062691289 @default.
• W2552649200 creator A5068862906 @default.
• W2552649200 creator A5079158736 @default.
• W2552649200 creator A5083349008 @default.
• W2552649200 creator A5087799564 @default.
• W2552649200 date "2011-11-18" @default.
• W2552649200 modified "2023-09-28" @default.
• W2552649200 title "Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd" @default.
• W2552649200 doi "https://doi.org/10.1182/blood.v118.21.323.323" @default.
• W2552649200 hasPublicationYear "2011" @default.
• W2552649200 type Work @default.
• W2552649200 sameAs 2552649200 @default.
• W2552649200 citedByCount "1" @default.
• W2552649200 countsByYear W25526492002012 @default.
• W2552649200 crossrefType "journal-article" @default.
• W2552649200 hasAuthorship W2552649200A5004386819 @default.
• W2552649200 hasAuthorship W2552649200A5009314752 @default.
• W2552649200 hasAuthorship W2552649200A5010176911 @default.
• W2552649200 hasAuthorship W2552649200A5012866839 @default.
• W2552649200 hasAuthorship W2552649200A5017690247 @default.
• W2552649200 hasAuthorship W2552649200A5018552863 @default.
• W2552649200 hasAuthorship W2552649200A5021394406 @default.
• W2552649200 hasAuthorship W2552649200A5035905546 @default.
• W2552649200 hasAuthorship W2552649200A5037882458 @default.
• W2552649200 hasAuthorship W2552649200A5045667573 @default.
• W2552649200 hasAuthorship W2552649200A5051154663 @default.
• W2552649200 hasAuthorship W2552649200A5060783496 @default.
• W2552649200 hasAuthorship W2552649200A5062691289 @default.
• W2552649200 hasAuthorship W2552649200A5068862906 @default.
• W2552649200 hasAuthorship W2552649200A5079158736 @default.
• W2552649200 hasAuthorship W2552649200A5083349008 @default.
• W2552649200 hasAuthorship W2552649200A5087799564 @default.
• W2552649200 hasConcept C126322002 @default.
• W2552649200 hasConcept C128057223 @default.
• W2552649200 hasConcept C203014093 @default.
• W2552649200 hasConcept C2777288759 @default.
• W2552649200 hasConcept C2777408962 @default.
• W2552649200 hasConcept C2777921159 @default.
• W2552649200 hasConcept C2779972918 @default.
• W2552649200 hasConcept C2781059491 @default.
• W2552649200 hasConcept C2909675724 @default.
• W2552649200 hasConcept C2911091166 @default.
• W2552649200 hasConcept C71924100 @default.
• W2552649200 hasConcept C90924648 @default.
• W2552649200 hasConcept C98274493 @default.
• W2552649200 hasConceptScore W2552649200C126322002 @default.
• W2552649200 hasConceptScore W2552649200C128057223 @default.
• W2552649200 hasConceptScore W2552649200C203014093 @default.
• W2552649200 hasConceptScore W2552649200C2777288759 @default.
• W2552649200 hasConceptScore W2552649200C2777408962 @default.
• W2552649200 hasConceptScore W2552649200C2777921159 @default.
• W2552649200 hasConceptScore W2552649200C2779972918 @default.
• W2552649200 hasConceptScore W2552649200C2781059491 @default.
• W2552649200 hasConceptScore W2552649200C2909675724 @default.
• W2552649200 hasConceptScore W2552649200C2911091166 @default.
• W2552649200 hasConceptScore W2552649200C71924100 @default.
• W2552649200 hasConceptScore W2552649200C90924648 @default.
• W2552649200 hasConceptScore W2552649200C98274493 @default.
• W2552649200 hasLocation W25526492001 @default.
• W2552649200 hasOpenAccess W2552649200 @default.
• W2552649200 hasPrimaryLocation W25526492001 @default.
• W2552649200 hasRelatedWork W2397097992 @default.
• W2552649200 hasRelatedWork W2475878607 @default.
• W2552649200 hasRelatedWork W2546313647 @default.
• W2552649200 hasRelatedWork W2549661550 @default.
• W2552649200 hasRelatedWork W2556838688 @default.
• W2552649200 hasRelatedWork W2559808144 @default.
• W2552649200 hasRelatedWork W2559903373 @default.
• W2552649200 hasRelatedWork W2562731863 @default.
• W2552649200 hasRelatedWork W2566982221 @default.
• W2552649200 hasRelatedWork W2576357940 @default.
• W2552649200 hasRelatedWork W2576796461 @default.
• W2552649200 hasRelatedWork W2582699834 @default.
• W2552649200 hasRelatedWork W2584063281 @default.
• W2552649200 hasRelatedWork W2587476742 @default.
• W2552649200 hasRelatedWork W2596863677 @default.
• W2552649200 hasRelatedWork W2979951816 @default.
• W2552649200 hasRelatedWork W2981433435 @default.
• W2552649200 hasRelatedWork W3001758012 @default.
• W2552649200 hasRelatedWork W3001866660 @default.
• W2552649200 hasRelatedWork W3180209262 @default.
• W2552649200 isParatext "false" @default.
• W2552649200 isRetracted "false" @default.
• W2552649200 magId "2552649200" @default.
• W2552649200 workType "article" @default.